It used to be that when baseball did things with its drug program, the league was accused of merely being reactive in an effort to calm down P.R. problems. If baseball had merely jacked up penalties for drug offenses — which they are reportedly doing — one might arguably say that’s what MLB was doing here, as a reaction to Biogenesis stuff. But, according to this Bob Nightengale report — from an unnamed source, so the specifics could still change — that’s not all they’re doing:
The new agreement will not only increase the drug penalties, but also implement widespread carbon isotope testing, the official said, hoping to dramatically increase the detection of a synthetic testosterone.
That’s a big deal, because the biggest problem with the Biogenesis thing wasn’t that it was somehow different or more insidious than your usual run-of-the-mill cheating, it’s that MLB didn’t catch the guys without help of an alternative newspaper in Miami. If MLB catches A-Rod on a drug test in 2012, it’s a totally different situation. Other players involved in Biogenesis may stop using. A protracted dispute about the length of penalties is not had and that arbitration from last year doesn’t exist. Toughening the testing and not letting players who use PEDs feel like they can get away with it is essential to cutting down on PED use.
But of course, increased penalties are part of the system too:
The official said first-time offenses will be 80 games, an increase from 50, and a second offense will be for an entire 162-game season instead of 100 games. There will be a lifetime suspension for a third offense.
I have no problem with this. It’s what the players want, and that’s the most important thing. It isn’t terribly draconian yet it does raise the stakes. Most importantly, there have been reports that there will be safeguards in place for players who can show that they inadvertently took a PED, so the situation that is most worrisome — a guy’s career being put at risk for an honest mistake — is off the table.
Interesting times for what many consider to be U.S. sports’ strongest drug program.
The Associated Press is reporting that the Cubs and starter Jake Arrieta have avoided arbitration, agreeing to a $10.7 million salary for the 2016 season. That marks the highest salary on a one-year deal for a pitcher with four years of service, the AP notes. Arrieta and the Cubs were set to go before an independent arbitrator but now can simply focus on the season ahead.
Arrieta, 29, is in his second of three years of arbitration eligibility. He had filed for $13 million while the Cubs countered at $7.5 million. The $5.5 million gap was the largest among players who did not come to terms with their respective teams by the January deadline. The $10.7 million salary is $450,000 above the midpoint between the two submitted figures.
Arrieta won the National League Cy Young Award for his performance this past season, narrowly edging out Zack Greinke, then with the Dodgers. Arrieta led the majors with 22 wins, four complete games, and three shutouts. With that, he compiled a 1.77 ERA and a 236/48 K/BB ratio across 229 innings.
Once a top prospect in the Orioles’ minor league system, Arrieta struggled in the majors but found immediate success with the Cubs in 2013 after the O’s traded him along with Pedro Strop in exchange for Steve Clevenger and Scott Feldman.
Per Baseball America’s Matt Eddy, the Giants have signed infielder Conor Gillaspie to a minor league deal. Gillaspie was selected by the Giants in the supplemental round of the 2008 draft, then was traded to the White Sox in February 2013.
Gillaspie, 28, hit a meager .228/.269/.359 with four home runs and 24 RBI in 253 plate appearances between the White Sox and Angels during the 2015 season. Almost all of his playing time has come at third base but he can also play first base if needed.
The Giants, thin on depth, will allow Gillaspie to audition in spring training for a spot on the 25-man roster.
Jon Morosi of FOX Sports reports that free agent reliever Joe Nathan, recovering from Tommy John surgery, plans to pitch in 2016 according to his agent Dave Pepe. According to Pepe, Nathan’s workouts are “going well” and the right-hander is “definitely planning on playing this year.”
Nathan, 41, got the final out on Opening Day (April 6) against the Twins before going on the disabled list with a flexor strain in his right elbow, causing him to miss the next 161 games. He will likely be able to contribute out of the bullpen in late May or early June if he has no setbacks. On a minor league deal or incentive-laden major league deal, Nathan could make for a low-risk gamble.
Over a 15-season career that dates back to 1999 (he did not pitch in the majors in 2001 or 2010), Nathan has 377 saves with a 2.89 ERA and a 967/340 K/BB ratio over 917 innings.
On Thursday, we learned that the Diamondbacks were still considering free agent reliever Tyler Clippard. You can add the Rays to the list as well, per Marc Topkin of the Tampa Bay Times.
The Rays traded lefty reliever Jake McGee to the Rockies in exchange for outfielder Corey Dickerson in late January, so Clippard would be able to slot right in behind closer Brad Boxberger. Clippard, 30, compiled a 2.92 ERA with 64 strikeouts and 31 walks over 71 innings in a season split between the Athletics and Mets. The strikeout rate was at its lowest since the right-hander become a full-time reliever in 2009, and his walk rate was at its highest since 2010, which may be a factor in his still being a free agent in February.